Home » Interim Data From Phase II Study of Combination Regimens Including VX-222, Incivek Suggest Potential to Treat Genotype 1 Hepatitis C
Interim Data From Phase II Study of Combination Regimens Including VX-222, Incivek Suggest Potential to Treat Genotype 1 Hepatitis C
Vertex Pharmaceuticals announced interim results from ZENITH, an ongoing Phase II study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (400 mg or 100 mg) in combination with Incivek (telaprevir) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.
Financial Post
Financial Post
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May